Seed Biotech

What Seed Biotech does

Seed Biotech, Inc. is a privately held manufacturer of biologic allograft products derived from human placental tissue, organized as a Texas corporation with operational and administrative headquarters in Chattanooga, Tennessee. The company was founded in 2012 by Christian (C.W.) Early and Ryanne Early and operated from Dallas, TX for 12 years before completing a multi-phase relocation to Chattanooga in January 2024. Its sole currently marketed product is Aril®, an acellular allograft amniotic membrane processed through proprietary, exclusively licensed technology that combines tissue procurement, decellularization, and preservation methods to remove cellular content while preserving the extracellular matrix (ECM), achieving greater than 95% DNA reduction validated on a lot-to-lot basis. Aril is packaged in a double-pouch system with room temperature stability, precision-cut as a single layer of amnion shaped as an ellipse or disc, and subjected to low-dose gamma irradiation. The company voluntarily discontinued its Petil product line in August 2024 following FDA regulatory assessments.

The company is an FDA-registered human tissue establishment (21 CFR Part 1271) with AATB accreditation for the processing, storage, and distribution of musculoskeletal tissue, and holds active state tissue bank licenses in New York, California, Delaware, Illinois, and Oregon. Seed Biotech sells Aril for homologous use in ophthalmology, orthopedic, spinal, wound covering, and general surgical applications, reaching physicians through independent sales distributors with specialty expertise, direct sales engagement, and participation in AAOS, AAO, and NASS industry conferences. Revenue is generated primarily through one-time product sales of Aril grafts, with secondary OEM manufacturing services offered to other biologics firms leveraging the company's proprietary processing capabilities. Pricing is determined through sales quotes and contract negotiations; no public pricing is disclosed. The company remains family-controlled with no disclosed external institutional investors, venture capital, or private equity backing.

Scale signals are modest: 11-50 employees, a cumulative 10,000+ Aril units delivered by December 2015, and multi-state but US-only commercial reach. The proprietary processing know-how, regulatory credentials, and targeted specialty-physician channels constitute the principal competitive assets; the Petil discontinuation and absence of external capital are the notable recent constraints on growth posture.

Name

Seed Biotech

Legal name

Seed Biotech, Inc.®

Website

https://seedbiotech.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

11–50 employees

Short description

Seed Biotech is a Chattanooga, Tennessee-based manufacturer of Aril®, an acellular allograft amniotic membrane product derived from human placental tissue for ophthalmic, orthopedic, spinal, and wound care surgical applications, sold to specialty physicians through independent distributors and direct sales.

Ownership category

akta.pro rank

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Operations, Supply Chain, Marketing or Sales, Personnel, Infrastructure

Revenue model

1. Aril Product Sales: Sale of Aril acellular allograft amniotic membrane products derived from human placental tissue for use in orthopedic, surgical, ophthalmology, spinal, and wound covering applications.
2. OEM Manufacturing Services: Seed Biotech offers OEM manufacturing capabilities leveraging their proprietary processing technologies for tissue-based products, serving other companies in the biologics space.
3. Distributor Sales: Products distributed through independent sales distributors who sell to healthcare providers in ophthalmic, orthopedic, and spinal industries.

Go-to-market motion3 records

Distribution channels1 record

Marketing channels4 records

Core offering

Seed Biotech, Inc.® is a manufacturer of advanced biologic products derived from human tissue, with a core focus on producing Aril® — an acellular allograft amniotic membrane derived from human placental tissue using proprietary decellularization and preservation technologies. The company also offers OEM manufacturing capabilities for tissue-based products to other companies in the biologics space. Products are intended for homologous use across orthopedic, surgical, ophthalmology, spinal, and wound covering applications.

Product overview

Seed Biotech, Inc.® is a biotech company manufacturing advanced biologic products derived from human tissue. Their primary product is Aril® - an acellular allograft amniotic membrane derived from human placental tissue. The company previously offered a Petil product line which was voluntarily discontinued in August 2024. All manufacturing is centered around their proprietary tissue procurement, decellularization, and preservation technologies.

Differentiator

Problem solved

Functional benefit

Brands

• Aril®: Acellular Allograft Amniotic Membrane - a room temperature stable allograft derived from human placental tissue, configured as a precision cut single layer of amnion shaped as an ellipse or disc. Intended for homologous use in orthopedic, surgical, ophthalmology, spinal and wound covering applications.

Products and services

• Aril® - Acellular Allograft Amniotic Membrane Aril® is a room temperature stable acellular allograft amniotic membrane derived from human placental tissue, configured as a precision cut single layer of amnion shaped as an ellipse or disc. Post-decellularization and stabilization, it is packaged in a double pouch system and subjected to low dose gamma irradiation, achieving greater than 95% DNA reduction. Intended for homologous use by surgeons and healthcare providers in orthopedic, surgical, ophthalmology, spinal, and wound covering applications.
• OEM Manufacturing Services Seed Biotech offers OEM manufacturing capabilities leveraging its proprietary tissue procurement, decellularization, and preservation technologies to produce tissue-based products for other companies in the biologics space. The service capitalizes on the company's FDA-registered human tissue establishment status and AATB-accredited processing capabilities.

Quantifiable outcome

• Greater than 95% DNA reduction in tissue products, validated on a lot-to-lot basis
• +2 more outcomes

Named customers2 records

Segments5 records

Ideal customer profiles5 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators4 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Smith+Nephew: Smith+Nephew is a global medical device company with significant wound care and orthopedics franchises, including skin substitutes and tissue-based products that overlap with Aril's wound covering and orthopedic applications. It is a broad incumbent competing at the indication level rather than as a pure amniotic membrane specialist.
• Integra LifeSciences: Integra LifeSciences is a large public medical device and regenerative technologies company selling dermal matrices, amniotic tissue grafts (e.g., AmnioExcel, BioDOptic), and wound care products. It competes with Seed Biotech in ophthalmology and surgical wound care, with much broader portfolio scale.
• Organogenesis: Organogenesis is a publicly traded regenerative medicine company selling amniotic and placental allografts (e.g., Apligraf, Affinity, NuShield) into wound care, surgical, and orthopedic markets. Comparable as a broader incumbent in the same tissue biologics category, with deeper commercial scale.
• RTI Surgical: RTI Surgical is a tissue-based implant manufacturer producing allografts and xenografts for spine, orthopedics, and surgical applications. Seed Biotech's CEO previously worked at RTI; the two compete for surgeon accounts in spine and orthopedics, with RTI operating at substantially larger scale.
• Arthrex: Arthrex is a major private orthopedic device and biologics company selling grafts and tissue products for sports medicine, orthopedics, and spine. It is a broad incumbent that competes with Seed Biotech's orthopedic and spine indications, though it does not focus specifically on amniotic membrane.

Direct peers

• AlloSource: AlloSource is an AATB-accredited tissue bank producing allografts for orthopedic, spine, sports medicine, and wound care. It is a direct peer in human tissue processing, with similar regulatory positioning and overlapping surgeon customers in orthopedics and spine.
• MTF Biologics: MTF Biologics is a non-profit tissue bank that processes and distributes allograft tissue (including amniotic and placental membranes) for sports medicine, orthopedics, and wound care. Seed Biotech's CEO previously worked at MTF, and the two compete in placental tissue procurement and processing.
• Amniox Medical (TissueTech): Amniox Medical, part of TissueTech, markets cryopreserved amniotic membrane products (e.g., Prokera, AmnioGuard) primarily for ophthalmology and surgical applications. It is a direct peer in amniotic membrane tissue processing, with comparable indications and customer base.
• MiMedx Group: MiMedx is the largest US-focused marketer of dehydrated amniotic membrane allografts (e.g., EpiFix, AmnioFix) for wound care, orthopedic, and surgical applications. It is the most direct competitor to Seed Biotech's Aril given overlapping technology, indications, and surgeon customer base.

Emerging players

• Axolotl Biologix: Axolotl Biologix is an emerging regenerative medicine company selling amniotic and placental tissue allografts into orthopedics, wound care, and pain management. It is comparable to Seed Biotech as a smaller, growth-stage player in the same placental tissue category, though with a different geographic and channel focus.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/SeedBiotech

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seed Biotech